Twist Bioscience Forecasts Q3 Revenue Between $114M and $115M
TWST has more than doubled off its 52-week low of $23.3 on elevated volume (2.0× avg).
Summary
Twist Bioscience has issued its revenue guidance for the third quarter, projecting sales to be in the range of $114 million to $115 million. This forward-looking financial update is new information and was not present in the recent routine SEC filings. For traders, this guidance is a critical data point that will immediately be benchmarked against current analyst consensus estimates, likely influencing the stock's trajectory as investors adjust their valuation models. The market's reaction will depend heavily on how this range compares to Wall Street's expectations, making the upcoming earnings call a key event to watch.
At the time of this announcement, TWST was trading at $59.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $23.30 to $66.06. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.